Viro-Immunologic Efficacy, Tolerability of Dolutegravir-Based Regimens for Acute HIV
Dolutegravir-based regimens in patients with acute HIV-1 infections who started ART early showed good viro-immunologic efficacy.
HIV/AIDS
Effect of Daily vs Event-Driven PrEP on HIV and STI Incidence in MSM
The incidence of STIs was higher among men who are HIV negative and have sex with men using daily PrEP compared with those using event-driven PrEP.
SNPs Associated With Long-Term Non-Progressors HIV Phenotype
Several single nucleotide polymorphisms located within the major histocompatibility complex region related to the long-term non-progressors phenotype were confirmed.
HIV Infection Increases Risk for Cardiovascular Disease and Stroke
Findings reinforce the importance of primary prevention of cardiovascular disease in people living with HIV.
Awareness, Use of PrEP Increasing Among Men Who Have Sex With Men
There has been a recent increase in the awareness and use of HIV PrEP among MSM.
No Substantial Difference in HIV Risk Using Injectable, Intrauterine, or Implantable Contraceptives
When comparing hormonal contraceptive methods, particularly IM depot medroxyprogesterone acetate with an IUD and a levonorgestrel implant, there was no substantial difference in HIV risk among African women.
Stone Formation in an HIV Patient Two Years After Stopping Ritonavir
A recently published report describes the case of a 33-year-old female patient with HIV who experienced ritonavir-induced nephrolithiasis 2 years after discontinuing the medication.
Disseminated Tuberculosis in Refugees Without HIV: Diagnosis and Treatment
Treating refugee patients with severe disseminated tuberculosis without HIV infection presents unique diagnostic and therapeutic challenges.
FDA Eliminates REMS for Truvada, PrEP Generics
In 2012, the FDA established the Truvada REMS for PrEP which required manufacturers to provide training materials, now that is no longer needed.
Increased Risk for Type 2 Diabetes in People With HIV and Lipodystrophy
People living with HIV, non-alcoholic fatty liver disease, and antiretroviral-associated lipodystrophy may be at an increased risk of developing type 2 diabetes.
Next post in HIV/AIDS
